High Court's Myriad Ruling Won't Crush Biotech Industry
The U.S. Supreme Court's ruling Thursday invalidating Myriad Genetics Inc.'s patents on isolated human genes won't deal a serious financial blow to the biotechnology industry, and could even strengthen it by...To view the full article, register now.
Already a subscriber? Click here to view full article